These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23725475)

  • 41. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.
    Revelli A; Chiado' A; Guidetti D; Bongioanni F; Rovei V; Gennarelli G
    J Assist Reprod Genet; 2012 Sep; 29(9):869-75. PubMed ID: 22644636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
    Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
    Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
    Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
    Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low dose clomiphene citrate as a mild stimulation protocol in women with unsuspected poor in vitro fertilization result can generate more oocytes with optimal cumulative pregnancy rate.
    Ochin H; Ma X; Wang L; Li X; Song J; Meng Y; Shen J; Cui YG; Liu J
    J Ovarian Res; 2018 May; 11(1):37. PubMed ID: 29728130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of luteinising hormone gene polymorphism on the outcomes of
    Ku Y; Hong MA; Chae SJ; Lim KS; Lee WD; Lim JH; Choi YM
    J Obstet Gynaecol; 2021 Oct; 41(7):1092-1096. PubMed ID: 33241699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of low day 3 luteinizing hormone levels on in vitro fertilization treatment outcome.
    Noci I; Maggi M; Fuzzi B; Biagiotti R; Ricci F; Marchionni M
    Gynecol Endocrinol; 2000 Oct; 14(5):321-6. PubMed ID: 11109971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction.
    Balasch J; Creus M; Fábregues F; Civico S; Carmona F; Puerto B; Casamitjana R; Vanrell JA
    J Assist Reprod Genet; 2001 May; 18(5):250-6. PubMed ID: 11464575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study.
    Weigert M; Krischker U; Pöhl M; Poschalko G; Kindermann C; Feichtinger W
    Fertil Steril; 2002 Jul; 78(1):34-9. PubMed ID: 12095487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
    Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
    Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Estimated Good Prognosis Patients Could Unexpected "Hyporesponse" to Controlled Ovarian Stimulation be Related to Genetic Polymorphisms of FSH Receptor?
    Alviggi C; Conforti A; Caprio F; Gizzo S; Noventa M; Strina I; Pagano T; De Rosa P; Carbone F; Colacurci N; De Placido G
    Reprod Sci; 2016 Aug; 23(8):1103-8. PubMed ID: 26902430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
    Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
    Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone.
    Messinis IE; Milingos S; Zikopoulos K; Hasiotis G; Seferiadis K; Lolis D
    Hum Reprod; 1998 Sep; 13(9):2415-20. PubMed ID: 9806260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study.
    Qiu Q; Huang J; Li Y; Chen X; Lin H; Li L; Yang D; Wang W; Zhang Q
    Hum Reprod; 2020 Jun; 35(6):1411-1420. PubMed ID: 32383771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.